Overview

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the effect of febuxostat on tranilast PK and PD as measured by reduction in serum uric acid levels.
Phase:
Phase 2
Details
Lead Sponsor:
Nuon Therapeutics, Inc.
Treatments:
Febuxostat
Tranilast